Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: A call for greater cognizance

Ju Dong Yang, Mohit Girotra, Alejandro Restrepo, Sarah Waheed, Bart Barlogie, Andres Duarte-Rojo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Hepatitis B virus (HBV) reactivation is a well-established complication of severe immunosuppression in patients with hematologic malignancy and positive hepatitis B surface antigen (HBsAg). Patients who receive high-dose chemotherapy, corticosteroids, rituximab, or have a bone marrow transplant are particularly at increased risk for HBV reactivation. However, limited information is available in the literature regarding HBV reactivation in patients with isolated anti-HBc, particularly in the setting of multiple myeloma (MM). We report two cases of HBV reactivation in MM patients with isolated anti-HBc positive with a rather atypical presentation. In conclusion, our cases highlight that clinicians need to be cognizant about this potentially fatal but preventable complication of chemotherapy and immunosuppression.

Original languageEnglish (US)
Pages (from-to)461-465
Number of pages5
JournalAnnals of Hepatology
Volume13
Issue number4
DOIs
StatePublished - 2014

Keywords

  • Bone marrow transplant
  • Chemotherapy
  • Hematologic malignancy
  • Viral hepatitis

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: A call for greater cognizance'. Together they form a unique fingerprint.

Cite this